Posted in Regulatory IO Shuts Down Following Regulatory Roadblocks April 1, 2026 BioSpace The FDA advised IO Biotech last year to hold off on filing an approval application for its cancer vaccine Cylembio, pointing to a failed Phase 3 study in frontline advanced melanoma. RegulatoryRead full story